DDIT3 and Familial prostate cancer: Celecoxib is an FDA-approved nonsteroidal anti-inflammatory drug that can enhance TRAILR2 expression in conventionally cultured colon and prostate cancer cells, presumably through inducing ER stress and the expression of CHOP, a major ER stress-induced transcription factor known to promote TRAILR2 expression [17, 18].